Table 3.
HIV-1-Infected Patients Failing on Raltegravir-Based Regimen with Primary and/or Secondary (Compensatory) Integrase Strand Transfer Inhibitor Mutations
| INSTI susceptibility | ||||
|---|---|---|---|---|
| Primary/secondary mutations | n (%) | DTG | RAL | EVG |
| M50I | 1 (2.0) | S | S | S |
| M50IM | 1 (2.0) | S | S | S |
| M50I, L74I | 1 (2.0) | S | S | S |
| T97A | 1 (2.0) | S | P | P |
| T97A, G163R, L74M | 3 (5.8) | S | L | L |
| N155H | 2 (4.0) | P | H | H |
| N155H, M50I | 1 (2.0) | P | H | H |
| N155H, T97A | 1 (2.0) | P | H | H |
| N155H, T97AT | 1 (2.0) | P | H | H |
| N155NH, T97AT, M50L | 1 (2.0) | P | H | H |
| N155H, T97A, E157Q, L74I | 1 (2.0) | P | H | H |
| N155H, E157Q, G163R, M50L, L74I | 1 (2.0) | P | H | H |
| Y143S, T97A | 1 (2.0) | S | H | H |
| Y143R, T97A | 2 (4.0) | S | H | L |
| Y143R, T97AT, G163R | 1 (2.0) | P | H | I |
| Y143R, T97A, M50I, L74LM | 1 (2.0) | P | H | I |
| E138A, T97A, V151A | 1 (2.0) | P | I | I |
| E138A, G140A, Q148R, G163R | 1 (2.0) | H | H | H |
| E138K, G140A, S147G, Q148K | 1 (2.0) | H | H | H |
| T66AIV, T97A | 1 (2.0) | S | L | H |
| T66A, T97A, G163R, L74M | 1 (2.0) | S | I | H |
Secondary mutations (not included in the table) found in N, FF, and SF, were classified as follows; M50I was found in 12 (7.5%) of FF, 4 (3.3%) of SF, and 7 (8.0%) of N. L74M found in 1 (0.8%) of SF and 1 (1.1%) of N. T97A was found in 8 (5.0%) of FF, 9 (7.4%) of SF, and 7 (8.0%) of N. E157Q was found in 2(1.2%) of FF and 1 (1.1%) of N. In bold, the major INSTI primary resistance mutations, which confer resistance to INSTIs.
FF, first-line failures; SF, second-line failures; H, high-level resistance; I, intermediate-level resistance; L, low-level resistance; S, susceptible genotype.